Komori
Astena Holdings (8095) · RiskFirst stated

Delays in drug development due to difficulties recruiting clinical trial participants

First written in FY2021-Q2. . Latest entry: FY2021-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Clinical trial delays due to difficulty securing trial participantsA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021-Q2First statedAnnual report

    「The pharmaceutical CDMO market was also experiencing delays in pharmaceutical development and other issues because of difficulties securing clinical-trial participants.」

    It was stated that difficulty securing clinical trial participants in the CDMO market was causing actual delays in pharmaceutical development.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Astena Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.